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1. Introduction 
Different populations of cancer cells co-exist within the same tumor; some have properties 
that closely resemble those of normal stem cells, which gave rise to the concept of cancer 
stem cells. Interestingly, these particular cancer cells express the same surface markers as 
normal stem cells, suggesting that cancer can sometimes arise from the malignant 
transformation of stem cells, such as established for some leukemias. The cancer stem cell 
model predicts that, even if "conventional" cancer cells can be killed, only the destruction of 
cancer stem cells allows full recovery. This demonstrates the importance of treatments 
targeting cancer stem cells for patient outcome. Therapeutic innovations will emerge from a 
better understanding of the biology and environment of cancer stem cells. Indeed, the tumor 
environment can create a niche favoring the survival and proliferation of cancer stem cells. 
It also contributes to resistance against therapy-induced apoptosis by providing both 
physical and physiological protection. Clinically, it is crucial to get rid of these treatment-
resistant quiescent cells and to adapt the therapeutic strategy to reach the cancer stem cells 
sheltered in niches. In fact, most cancers likely recur because cancer stem cells escape 
treatment, survive and regenerate the tumor. Current hypotheses under evaluation suggest 
that this resistance may be due to the preservation of normal stem cell protective 
mechanisms such as their location in a niche, deregulation of drug efflux/influx transporter 
expression or alterations in apoptotic, cell cycle and DNA repair mechanisms. In this 
context, one of the key issues is that cancer stem cell self-renewal is dependent on close 
interactions with the stem cell niche which regulate the different developmental signaling 
pathways and are often found deregulated in cancer. However, investigations of the role of 
the microenvironment in adult stem cell transformation and resistance, especially in solid 
tissues, have started only recently, likely because of the major technical difficulties involved. 
Despite this delay, and thanks in part to studies in the hematopoietic system, a gold 
standard model for stem cell biology, great advances have been made in understanding the 
importance of the stem cell-microenvironment crosstalk in both normal and cancer tissues. 
We have now reached the point where conventional anti-cancer strategies can give way to 
more innovative combined therapy to target these interactions and “re-access” cancer stem 
cell regulation controls. Targeting these mechanisms by taking advantage of potential 
differences in the biology of normal and cancer stem cells, such as differences in surface 
phenotype, self renewal/quiescence and stem cell-niche interactions, might allow successful 
cancer stem cell targeting and improve cancer treatment outcome. This chapter focuses on 
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the main issues to be considered for efficient and specific targeting of cancer stem cells 
within their niche. First we will present the different kinds of adult somatic stem cell niches, 
their characteristics and functions in normal tissues, which have been particularly well 
described and studied in the hematopoietic system. We will review recent data on the 
control by the niche of cell self-renewal, quiescence, differentiation and survival/apoptosis. 
Then we will discuss the involvement of the cancer stem cell microenvironment in cancer 
initiation, in the maintenance of residual disease and in treatment escape, a combination of 
mechanisms that likely drive cancer relapse in both hematopoietic and solid tumors. In 
conclusion, we will discuss the main therapeutic approaches currently under development 
and evaluation for targeting interactions of cancer stem cells with their neighboring 
partners. It is already foreseeable that combinations of conventional therapeutic approaches 
with specific cancer stem cell-targeting treatments might efficiently cure cancer.  
2. Stem cell niches: a critical cell survival architect  
More than 30 years ago, the existence of special spatially defined areas that were suspected 
to supply factors necessary to the survival and development of cells capable to regenerate 
tissues in adult organisms was postulated (Schofield, 1978). It was suggested that the local 
environment was critical to maintain cell survival through the delivery of special signals by 
the so-called “niche” that directs cell proliferation, differentiation and apoptosis. A number 
of studies have clearly demonstrated that the stem cell niche constitutes a key regulator of 
stem-cell fate by balancing self-renewal and differentiation (Blanpain et al., 2004; Fuchs et 
al., 2004; Zhang et al., 2003; Calvi et al., 2003). This concept was later extended to solid 
tissues and cancers (Moore and Lemischka, 2006; Li and Neaves, 2006). Over the last 
decades the existence, composition and functions of adult stem cell niches have begun to be 
elucidated, mainly in the hematopoietic system and, more recently, in solid tissues. 
2.1 The hematopoietic model 
The concept of stem cell niche was first described in the hematopoietic system. It was 
proposed that the bone marrow environment, where hematopoietic stem cells reside, is 
capable to regulate the maturation of hematopoietic stem cells by controlling the balance 
between two main mechanisms, stem cell quiescence/maintenance, and differentiation and 
production of mature blood components (Schofield, 1978). However, in order to allow for 
tissue turnover or injury repair, the stem cell niche must also permit stem cell activation and 
recruitment for proliferation/differentiation (Schofield, 1978). The normal bone marrow 
microenvironment (the hematopoietic “niche”) regulates the dormancy, survival and non-
differentiation of hematopoietic stem cells (Li and Li, 2006) in response to various external 
signals, therefore constituting a dynamic system. In addition, the niche interacts with stem 
cells; it does not only behave as an active regulator but also receives feedback from stem 
cells which actively contribute to the organization of their own niche (Fuchs et al., 2004). 
Adhesion to both matrix proteins and stromal cells and exposure to their soluble factors 
(cytokines, morphogens) controls the self-renewal and differentiation of hematopoietic stem 
cells (Ross and Li, 2006). In this regard, mesenchymal stem cells have been shown to play a 
central role in the stem cell niche in hematopoietic and other tissues (Docheva et al., 2007; 
Dazzi et al., 2006). They can differentiate into osteoblasts, the major regulators of 
hematopoiesis, and secrete many matrix proteins, morphogens, growth factors and 
cytokines (Calvi et al., 2003; Zhang et al., 2003). Interestingly, it has also been reported that 
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infusion of ex vivo-expanded mesenchymal stem cells enhances hematopoietic stem cell 
engraftment, thus participating actively in stem cell homing (Dazzi et al., 2006). Immune 
cells are also an important component of the stem cell niche (Yang, 2007). Mesenchymal 
stem cells inhibit the immunological functions of antitumor lymphocytes such as natural 
killer cells (Sotiropoulou et al., 2006) and cytotoxic T lymphocytes (Djouad et al., 2003). 
Interactions between the different components appear to be important in controlling stem 
cell function, as illustrated by the impact of mesenchymal stem cells on immune cells 
(Benvenuto et al., 2007). Finally, inflammatory and oxidative stresses, associated with 
microenvironmental elements, constitute important regulators of hematopoietic stem cell 
functions (Ito et al., 2006). Recently, a step forward was made with the identification of 
different subsets of hematopoietic stem cells such as dormant or homeostatic stem cells. This 
discovery immediately implied the likely existence, within the bone marrow, of distinct 
hematopoietic niches supporting and controlling the different hematopoietic stem cell types. 
Two main types of niches are commonly distinguished according to their location, 
composition and function on hematopoietic stem cells: the osteoblastic/endosteal niche and 
the vascular niche. In situ experiments have located hematopoietic stem cells within the 
trabecular-bone area (Zhang et al., 2003). The niche that contains the most dormant stem 
cells is described as a hypoxic place close to the endosteum which contains osteoblasts, 
fibroblasts, osteoclasts, perivascular structures and sympathetic neurons (Burness and 
Sipkins, 2010; Trumpp et al., 2010).  The control of the size and composition of the niche has 
been reported to involve a number of different factors such as Notch or the Bone 
Morphogenetic Proteins (Kiel and Morrison, 2008; Zhang et al., 2003). Interestingly, this 
family of proteins has also been known for several years to be a key factor in the control of 
hematopoietic stem cell fate (Sadlon et al., 2004; Maguer-Satta and Rimokh, 2004). In the 
bone marrow environment, hypoxia has been initially described to regulate hematopoietic 
differentiation, in particular toward the erythroid lineage, likely to counteract oxygen 
deprivation after an injury episode (Perry et al., 2007). Conversely, within the endosteal 
niche, the hypoxic environment appears to protect the long–lived, deeply dormant stem 
cells from the toxic effects of oxidative damage caused by reactive oxygen species that 
otherwise could conduct to the alteration of the stem cell pool. On the other hand, 
oxygenated perivascular niches represent a network of sinusoids composed of endothelial 
cells, reticular cells and megakaryocytes (Trumpp et al., 2010). Their function seems to 
promote hematopoietic stem cell proliferation and differentiation, in particular during blood 
recovery after an injury. Even if dormant cells could theoretically also locate in vascular 
niches, these niches remain the principal sites where bone marrow hematopoietic stem cells 
are mobilized to the peripheral circulation, together with differentiated hematopoietic cells 
(Burness and Sipkins, 2010). This mechanism is mainly regulated by the SDF-1/CXCR4 
chemokine pathway that directs the passage of the cells from or toward the bone marrow. 
To maintain blood homeostasis, a flux of homeostatic hematopoietic stem cells migrates 
from endosteal niches through perivascular niches to the circulation. Therefore a continuous 
traffic of hematopoietic stem cells is observed from one niche to another and to the 
peripheral circulation, then back to the bone marrow and supposedly to dormancy.  
2.2 Insight in solid tissue stem cell niches 
As in the hematopoietic system, the niche in solid tissues is defined as the physiological 
microenvironment which keeps the stem cells quiescent until their self-renewal. The same 
applies to other stem cell niches present in various tissues and containing various partners 
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(Blanpain et al., 2004; Moore and Lemischka, 2006). Despite the technical difficulties of 
investigating the niche composition, location and function in solid mammalian tissues, some 
examples have been reported in the neural system and in the intestinal and various other 
epithelia (Burness and Sipkins, 2010). A number of elements common to solid tissue and 
hematopoietic stem cell niches have then been identified, including cell-cell and cell-extra 
cellular matrix interactions, as well as diffusible signaling factors mediating signal 
transduction in order to maintain stem cell survival and self-renewal. For example, in the 
nervous system the functional interactions of the vascular niche between neural stem cells and 
endothelial cells through junctional contacts are involved in the increased proliferation of 
neural stem cells. Similar to neurogenic niches in the hippocampus, neurovascular interaction 
has been observed in the sub-ventricular zone where numerous polarized stem cells establish 
connections with the endothelial cells of blood vessels through long basal processes. These 
stem cells also extend short apical processes to connect to ependymal cells that line the surface 
of lateral ventricles (Vazin and Schaffer, 2010). Recent data in intestine, brain, hair follicle or 
skin suggest that, like hematopoietic stem cells in the bone marrow, two main categories of 
stem cell niches might exist in solid tissues. Evidence in support of this theory comes in part 
from the observation that in tissues containing low cycling stem cells, participation in 
homeostasis and repair requires that cells rapidly switch from a quiescent to proliferative state. 
As in the hematopoietic system, two functional types of niches could be distinguished, one 
allowing rapid entry into proliferation, as required for tissue regeneration, and one that would 
maintain long-term growth and self-renewal (Greco and Guo, 2010). Interestingly, another bi-
compartmentalization has been proposed for epithelial tissues based on cellular components 
of the niche. The two compartments would be the epithelial niche where stem cells are in 
direct contact with the basal lamina and the stromal niche where stem cells interact with 
another cell type in contact with basal lamina (Morrison and Spradling, 2008). Each type of 
epithelium has its own mechanism to regenerate from local stem cells. The different stem cell 
populations cooperatively regenerate all terminally differentiated cell types within the tissue. 
The microenvironment of epithelial stem cells is generally located near a basement membrane 
and the stem cells are part of the basal layer. Supportive cells present within the niche protect 
the stem cells from exogenous factors. Following differentiation, stem cell progenies migrate 
along the basement membrane and leave the niche (Verstappen et al., 2009). Epithelial niches 
might be limited by the presence of specific molecules within the extracellular matrix or on 
neighboring tissues. On the other hand, stromal niches appear to develop independently of the 
presence of stem cells and to maintain their morphology even after stem cell loss (Morrison 
and Spradling, 2008). Both types of niches depend on cell-cell junction molecules and stem 
cells are in contact with their progenies. In all cases and in any proposed classification, the role 
of niches in solid tissues is the same as in the hematopoietic system, namely to maintain and 
protect the stem cell pools which are crucial for tissue homeostasis. In all systems, this 
mechanism appears to be dependent on stem cell interactions with their close environment. A 
permanent dialogue through recurrent adhesion molecules such as cadherins or integrins is 
required to maintain stem cell architecture and shape, but this mechanism also constitutes a 
key regulator of asymmetrical division, and therefore self-renewal, as we will discuss now 
(Marthiens et al., 2010).  
3. The guardian of key features of stem cells 
The niche is critical to maintaining stem cell quiescence, the intrinsic self-renewal and 
undifferentiated character of resident stem cells, but it also regulates exogenous stem cells 
that tend to home back to that specific microenvironment.  
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3.1 Asymmetric cell division 
Regulating the balance between symmetrical and asymmetrical divisions is critical to 
maintain the proper number of stem cells within the niche and meeting the demand for 
differentiated cells in surrounding tissues. Asymmetric cell division is one of the key 
features of stem cells that allows simultaneous self-renewal and differentiation. Asymmetric 
division is the process by which a single cell gives rise to two different daughter cells, a 
major strategy for the generation of cell diversity during the development or renewal of an 
organism/organ/tissue (Fuchs et al., 2004). However, it is also important to note that 
asymmetric division is not the only way to maintain stem cell self-renewal since two 
identical daughter cells are also specified entirely by their position and external signals 
derived from cells outside the niche (Conti et al., 2005). In particular, this process has been 
reported to occur in stem cell amplification during regeneration (Morrison and Kimble, 
2006).  Experiments in Drosophila and Caenorhabditis elegans have identified three major steps 
to achieve asymmetrical division: establishment of polarity, localization of fate determinant 
to one or the other cell pole, and subsequent regulation of the plane of cell cleavage. Upon 
division, the fate determinants will be asymmetrically distributed between the two daughter 
cells, one of them retaining stem cell features while the other one is driven toward a more 
differentiated stage (Marthiens et al., 2010). A number of genetic determinants have been 
shown to be involved in the intrinsic mechanism that dictates asymmetrical division 
(Faubert et al., 2004) but the exact pathways involved and their connection with extrinsic 
elements are still under investigation. However, thanks to studies in animal models like 
Caenorhabditis elegans, great progress has been made in understanding how the stem cell 
niches give instructive signals to drive asymmetric divisions in order to orchestrate the flow 
and cell fate of committed progenitors in a spacio-temporally controlled fashion. 
Asymmetry can be governed by the proximity to the cellular environment, such as the 
defined niches, that exerts extrinsic physical tension to achieve asymmetrical distribution of 
the mitotic spindles. Astral microtubules are physical structures that determine centrosome 
and spindle positioning. The aster traction to one pole of the cell results from a complex 
network of interactions between cell surface molecules, intra-cellular microtubules and 
intrinsic elements. Certain adhesion molecules such as APC, cadherins and integrins, have 
been shown to be involved in this process (Fuchs et al., 2004; Marthiens et al., 2010). For 
example, the role of cell-to-cell interactions mediated by β1-Integrins is crucial for the 
maintenance of stemness, especially in the hematopoietic stem cells that home back to the 
bone marrow (Gottschling et al., 2007). Authors have shown that β1-integrins play a 
significant role not only in the interaction between hematopoietic stem cells and 
mesenchymal stem cells but also in the regulation of the long-term fate of hematopoietic 
stem cells by favoring initial self-renewing divisions and the survival of primitive 
hematopoietic stem cells. This role of β1 integrin in asymmetrical division has also been 
demonstrated in solid tissue stem cells such as in the skin or the mammary gland  
(Marthiens et al., 2010). Therefore close interactions between stem cells and their neighbor 
cells within the stem cell niche allow adhesion molecules to control the angle of cell division 
by interacting with astral microtubules that regulate centrosome positioning. In cancer, the 
loss of this ability of asymmetrical division is thought to lead to the over amplification of a 
pool of cells that progressively drives to tumorigenesis.  
3.2 Stem cell quiescence 
The crucial point for the body to achieve homeostasis throughout life is to be able to 
preserve the stem cell pools from exhaustion and alteration. To that aim, the body employs a 
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strategy involving specialized stem cell niches, such as the osteoblastic/endosteal niche in 
the hematopoietic system and the so-called epithelial niche for epithelium tissues that, by 
their defined composition, are capable to display quiescent signaling to the resident stem 
cells (Trumpp et al., 2010; Morrison and Spradling, 2008). In order to maintain stem cells 
through time, it is important that self-renewal divisions of dormant stem cells occur only 
transiently, for example in response to a physiological need or to injury. Niche components, 
such as extracellular matrix molecules (laminin, fibronectin, collagen, glycosaminoglycans), 
provide a physical framework and instructive signals that regulate stem cells, in particular 
by participating to the maintenance of cell quiescence. It has been described, for instance, 
that β-integrin regulates the maintenance of neural stem cells and directly induces the 
expression of other cell surface receptors that relay information to the neural stem cells. 
Extracellular-matrix molecules also serve to immobilize and locally increase the 
concentration of a number of soluble signaling molecules such as the Bone Morphogenetic 
Proteins, Sonic Hedgehog or Wingless proteins, involved in stem cell quiescence (Vazin and 
Schaffer, 2010). Several receptors have then been demonstrated to be involved in the specific 
signals that dictate stem cell quiescence, partly by preventing cell division and 
differentiation. These include the tyrosine kinase receptor Kit (i.e. CD117) that binds Stem 
Cell Factor (SCF), the receptor for angiopoietin 1 (ANG1) TIE2, the TromboPOietin (TPO) 
receptor (cytokine receptor MyeloProliferative Leukemia virus receptor, MPL) and the CXC-
chemokine receptor 4 (CXCR4) that binds the Stromal Derived Factor 1 (SDF1). Signaling 
response to their respective ligands inhibits the division of cells, thus preserving their 
dormancy. In addition, dormant niches seem to be dependent upon low oxygen 
concentration environment to maintain stem cell dormancy mainly through HIF1α signaling 
(Guitart et al., 2010; Diabira and Morandi, 2008; Eliasson et al., 2010; Moreno-Manzano et al., 
2010). In the hematopoietic system, it is now well known that hypoxia is one of the key 
factors of the endosteal niche that contribute to maintaining normal stem cells in a dormant 
stage (Trumpp et al., 2010). All these signals are actively coordinated and presented in a 
temporally and spatially regulated manner to ensure the balance between stem cell 
quiescence and activation (Trumpp et al., 2010).  
3.3 Stem cell fate 
To preserve the stem cell pool from exhaustion, self-renewal divisions of dormant 
hematopoietic stem cells seem to occur only transiently after injury or mobilization signals. 
In this particular situation which requires the release of stem cells from their dormant stage, 
both types of signals have been reported to induce a proteolytic environment that 
enzymatically cleaves physical hematopoietic-niche bonds. This allows stem cells to migrate 
from the endosteal niche to the vascular niche where they find proliferation/differentiation 
signals and eventually leave the bone marrow to be transported to the site of injury by the 
peripheral system (Trumpp et al., 2010). Therefore, the architectural design of a niche 
appears to be suited to particular needs of its resident stem cells and, conversely, stem cells 
may play an important role in organizing and specifying the niche as proposed in the 
context of breast by the dynamic reciprocity concept (Xu et al., 2009). One of the best 
described actors in self-renewal maintenance in different systems is the β1-Integrin. This 
protein belongs to the large family of heterodimeric receptors involved in cell-matrix and 
cell-cell adhesion. Integrins transduce both “Outside-In” and “Inside-Out” signals involved 
in cellular processes such as cell morphology, motility, proliferation, differentiation, 
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inhibition of apoptosis and likely much more (Ho and Wagner, 2007; Docheva et al., 2007; 
Gottschling et al., 2007; Dylla et al., 2004). In some cases, like in the neural system (Hall et 
al., 2006) or breast (Shackleton et al., 2006; Stingl et al., 2006), some integrins are even 
considered as stem cell markers. Their key role in the hematopoietic system has been largely 
documented, mainly through their binding to fibronectin (main ligand of ┚1 integrin) or, to 
a lesser extent, to VCAM-1 (Levesque and Simmons, 1999), in diverse processes of 
hematopoietic stem cell regulation such as self-renewal, differentiation, mobility and 
apoptosis (Hurley et al., 1997; Hurley et al., 1995; Jiang et al., 2000a; Prosper and Verfaillie, 
2001; Prosper et al., 1998; Priestley et al., 2006; Priestley et al., 2007; Scott et al., 2003). More 
recently their involvement in stem cell maintenance has been demonstrated in both murine 
(Taddei et al., 2008) and human (Bachelard-Cascales et al., 2010) breast and studies are 
currently investigating their role in the biology of stem cells in many other solid tissues. 
Understanding the fine-tuned regulation that switches stem cells from a deep dormant to a 
proliferating state is quite complex. As for quiescence maintenance, extracellular matrix-
bound molecules such as the Bone Morphogenetic Proteins (Vazin and Schaffer, 2010) could 
also serve as main regulators to control stem cell self-renewal, proliferation or commitment, 
as described by us in the hematopoietic system (Jeanpierre et al., 2008; Maguer-Satta et al., 
2006; Maguer-Satta and Rimokh, 2004; Maguer-Satta et al., 2003) or by others in the 
epithelial system (Blanpain and Fuchs, 2006), or for Notch and Sonic Hedgehog in the neural 
system (for review see (Fuchs et al., 2004; Morrison and Spradling, 2008)). Finally, stem cells 
respond differently to a two-dimensional substrate and a three-dimensional environment, 
thus activating different signaling pathways. Integrin signaling, for instance, is involved in 
extracellular matrix remodeling which controls the niche architecture and therefore impacts  
 
Autocrine
Structural
Solubles Factors
Circulating cells
Stromal Cells
Extra Cellular Matrix
Neural Cells
Blood vessel
O2
Stem 
Cells
Paracrine
Metabolic
Dormant
Stem Cells
Physical
 
Fig. 1. Parameters of stem cells niches that drive stem cells behavior and/or the reverse, 
summary of the main parameters involved in stem cell behavior such as dormancy or 
inversely their commitment, migration. The same elements are involved in the permanent 
dialogue that exists between stem cells and their niche going from the stem cell toward its 
environment to modify or regulate its function. Each of these elements can be affected 
during cell transformation inducing cancer stem cell escape, resistance and persistence.  
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stem cell behavior and tumorigenesis (Larsen et al., 2006). This has been demonstrated in 
normal adult stem cells using variations of matrix elasticity to drive stem cell fate (Engler et 
al., 2006). Moreover, matrix remodeling, notably proteolytic breakdown of fibronectin 
giving rise to biologically active peptides or to domains of interaction with morphogens or 
TGF┚ regulators, may be involved in the control of hematopoietic stem cell fate either by 
promoting cell proliferation or commitment toward specific lineages.  
The different niche types defined share common features and activate common signal 
transduction pathways to achieve the slow-cycling, self-renewing, undifferentiated state of 
their residents (Fig. 1). For that, several different pathways display a number of crosstalks 
and multigene redundancies. Conversely, each niche is composed of different types of non 
stem cells and stem cells that constitute this environment and a same signaling pathway can 
control different cellular functions. Altogether this strongly suggests that the critical genes 
involved in stem cell fate are likely to vary with the different stem cell types and their 
location, even if the general mechanisms controlling their behavior remain the same.  
4. The under-estimated initiator/actor of cancer 
There is growing evidence that, although it has long been largely under-evaluated, the 
tumor microenvironment plays a very active role in tumor initiation and progression. More 
than twenty years ago, a few people went against the strong wave of genetic promoters as 
the only explanation for the etiology of cancer, and claimed that “mutations were not all” in 
oncogenesis. At that time some scientist argued that the tumor environment was also a 
major actor in cancer pathogenesis and that it should be taken into account in studies that 
pretend to understand and treat cancer (Ronnov-Jessen and Bissell, 2009). With the 
discovery of cancer stem cells, focus turned to their specific microenvironment and studies 
tried to elucidate the function of their permanent dialogue. It took several decades to 
actually reach the point where the tumor environment was considered as a key player at all 
stages of cancer. This led to major observations and gave some insight in its role in cancer 
initiation, escape and resistance to treatments. The proof of concept came once more from 
the hematopoietic system where a key clinical observation was made. It is now trivial that 
the bone marrow microenvironment plays an important role in pathogenesis. A review 
providing compelling information about the hematopoiesis of donor cell leukemia strongly 
supports this “seed and soil” hypothesis that has been hanging around for years in the field 
of solid tumor metastasis research (Paget, 1989; Mueller and Fusenig, 2004; Demicheli, 2001; 
Greig and Trainer, 1986). The authors clearly underline that, though seemingly rare, 
leukemia sometimes occurs in normal donor hematopoietic cells transplanted to leukemia 
patients. The disease is then named Donor Cell Leukemia and must be distinguished from a 
relapse of the patient’s original malignancy as it constitutes a de novo leukemia affecting 
normal transplanted cells (Flynn and Kaufman, 2007). Therefore, it has become quite evident 
that the hematopoietic niche is involved in the transformation of normal donor cells into 
leukemia cells; this theory is supported by the fact that no cytogenetic abnormalities have 
been detected in donor cells. It is even suspected that, as the hematopoietic stem cells 
present in the graft are responsible for hematopoietic reconstitution in the recipient, Donor 
Cell Leukemia might arise from abnormal hematopoietic stem cell regulation by the 
patient's hematopoietic niche (Flynn and Kaufman, 2007). Therefore, the role of the tumor 
microenvironment in tumor initiation and progression through its different constituting 
elements (stromal and immune cells as well as extra cellular matrix molecules) is being 
www.intechopen.com
The Stem Cell Niche: The Black Master of Cancer   
 
223 
increasingly acknowledged. Two main hypotheses could explain features of cancer stem 
cells: one proposes that transformed stem cell-like populations progressively evade their 
niche control while the other one considers that the niche itself could be altered during 
oncogenesis. Actual data document both aspects, indicating that tumors arise from complex 
combinations of alterations that trigger both the malignant cells and their environment.  
4.1 Niche alteration: cause and consequence 
A first step to identify and understand the role of niche alteration in cancer development has 
been the characterization of the cellular content of the niche. In established leukemia, several 
lines of evidence demonstrate that both cell and matrix components of the bone marrow 
microenvironment, such as integrins, are clearly modified (Ruoslahti, 1999). Mesenchymal 
stem cell alterations have then been investigated and several changes have been identified in 
their transcriptome, phenotype and functions from myeloma patients (Arnulf et al., 2007; 
Corre et al., 2007). In a number of myeloid or lymphoid leukemias, profound alterations of 
the bone marrow environment, such as myelofibrosis, are frequently reported. In myeloma, 
osteolytic lesions and differential expression of integrins and cytokines correlate with early 
oncogenic events (Hideshima et al., 2004). In Chronic Myelogenous Leukemia, bone marrow 
macrophages impair the mesenchymal cell support of hematopoiesis (Bhatia et al., 1995a), 
whereas in Acute Myeloid Leukemia, fibronectin and Wnt ligands are overexpressed (Simon 
et al., 2005). Alterations of the ┚1 integrin, not in terms of membrane protein expression but 
rather as a defect in protein activation, has been shown to be involved in the loss of 
regulation of leukemic hematopoietic stem cells by the marrow stroma (Bhatia et al., 1995a; 
Bhatia et al., 1999; Jiang et al., 2000b; Jongen-Lavrencic et al., 2005; Lundell et al., 1997; 
Lundell et al., 1996). Original signaling pathways downstream of integrin ligation have been 
involved in normal and leukemic cell survival, proliferation and adhesion (Tabe et al., 2007; 
Dylla et al., 2004; Melikova et al., 2004). In solid tumors, integrins have also been involved at 
various levels in breast cancer biology, likely at the level of cancer stem cell (Bissell et al., 
2005; Park et al., 2006; Faraldo et al., 2005; Faraldo et al., 2002; Faraldo et al., 2000; Taddei et 
al., 2003). In addition, a deregulated signal transduction in leukemic cells may allow them to 
escape microenvironmental control (Astier et al., 2003; Wilson et al., 2004; De Waele et al., 
1999). Another example of niche alteration has been reported in solid tumors by pathologists 
who have described the frequent association of stromatogenesis and neoplasia. This 
stromatogenesis is an affection of the tumor-associated stroma characterized by many 
changes such as deregulated expression and organization of fibronectin and collagen, 
leading to modifications of the stroma-associated tumor that becomes more rigid. Other 
studies have shown that extracellular matrix stiffness perturbs the original epithelial 
morphogenesis by clustering integrins and inducing focal adhesion assembly to enhance 
specific signaling pathways (Paszek et al., 2005). Cells sense elevated extracellular matrix 
rigidity through their integrins and respond with modified signaling that in turn stimulate 
integrin expression or change their conformation to induce their activation. This response 
can be amplified by a signaling cascade involving different molecules (such as Rho, Rock, 
ERK) that drive surrounding cell proliferation and transformation and extracellular matrix 
rigidity (Larsen et al., 2006). As a consequence, the tumor microenvironment can send 
erroneous signals to niche cells, inducing accumulation of proteases and activation of 
soluble factors, all contributing to alter stem cell control. Altogether, these data indicate that 
most cancers are likely associated with modifications of the stem cell environment. One of 
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the consequences possibly contributing to cancer initiation is the deregulation of asymmetric 
division control by the niche. When the asymmetric division machinery is perturbed tumor 
growth is observed (Caussinus and Gonzalez, 2005). In support of this hypothesis is also the 
fact that some gene products that induce asymmetric cell divisions function as tumor 
suppressor genes, such as reported for APC in colorectal cancer and melanoma. Conversely, 
gene products that favor symmetric cell divisions act as oncogenes in mammalian cells, such 
as PKC in lung cancer. Symmetric division then not only favors the expansion of stem cell 
numbers but might also increase the risk of aneuploidy and accumulation of secondary 
mutations by impaired mechanisms controlling the mitotic machinery (Morrison and 
Kimble, 2006). It then becomes important to understand the consequences of this matrix 
remodeling on normal and cancer stem cell behavior, in particular for drug resistance.  
4.2 Cancer stem cells: natural reprogramming in “iPS” by the niche 
Of particular interest in the context of cancer, niches have been demonstrated to be capable 
of reprogramming cells. An experimentally-vacated ovarian germline stem cell niche 
induced the division of foreign surrounding somatic stem cells which then have given rise 
to ovarian follicle cells and allowed the dedifferentiation of ectopic follicle progenitor cells 
at earlier stages of differentiation. These experiments have established the fact that a niche 
is a stable structure capable to direct cell fate even outside its initial intrinsic 
differentiation program (Kai and Spradling, 2003). These observations might be in part 
explained by the reprogramming power of physical constraint. A very elegant study has 
demonstrated that simple physical constraint can drive stem cells toward one lineage 
rather than another, indicating that both physical and cellular properties of niches are 
important in the control of stem cell behavior  (Engler et al., 2006). In the past five years, 
stem cell research has made a major breakthrough by artificially inducing cell 
reprogramming. Yamanaka et al have developed a strategy that generates from mature 
differentiated cells a “stem cell-like” entity named iPS for "induced-Pluripotent Stem 
Cell". Reprogrammed cells display most of the properties of pluripotent stem cells, such 
as the ability to differentiate into functional mature cells, and present a number of 
epigenetic modifications (Boheler, 2009). It is intriguing that factors deregulated in the 
cancer niche, such as hypoxia, have recently been reported to significantly improve the 
iPS process (Yoshida et al., 2009). The origins of cancer stem cells are still debated and one 
can hypothesize that the transformation of a true stem cell, such as in Chronic 
Myelogenous Leukemia, is likely to be an infrequent event. Almost a decade ago, the 
option that cancer stem cells could arise from the reacquisition of stem cell characteristics 
emerged (Passegue et al., 2003). It is then tempting to suggest that one of the first steps in 
tumor initiation is the generation of cancer “iPS” induced by alterations occurring in the 
niche, such as a change in rigidity, extracellular matrix remodeling  or oxygen 
concentration  (Engler et al., 2006; Larsen et al., 2006; Heddleston et al., 2010). In support 
of this hypothesis is the fact that in cells classified as cancer stem cells the re-expression of 
embryonic genes or genes involved in self-renewal has often been described and shown to 
be involved in the cancer stem cell phenotype (Lessard and Sauvageau, 2003; Yin et al., 
2010; Godmann et al., 2009). Finally, the niche could induce genetic or epigenetic changes 
in cancer stem cells (or vice versa) as observed using the iPS technology (Boheler, 2009). 
These changes provide a growth advantage and induce a differentiation blockade, causing 
their transformation into cancer stem cells (Issa, 2007; Wang and Dick, 2005).  
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4.3 Factors that control key surviving pathways 
A large number of factors have been reported to favor cancer cell survival. Only a few 
particularly significant examples of the key role played by the niche in cancer stem cell 
behavior will be given here. The tumor microenvironment is often hypoxic, due essentially 
to chaotic vasculature, poor oxygen diffusion across the expanding tumor and irregular 
blood flow. The oxygenation status of tumor tissues cycles in both spatial and temporal 
manners. Several studies have shown that hypoxic conditions enhance the metastatic power 
of cancer cells likely through HIF-dependent pathways (Heddleston et al., 2010). During 
cancer initiation, a hypoxic environment might favor the transformation of the resident stem 
cells by potentiating the effect of genes associated with stemness like Notch. At the clinical 
level, there is a correlation between the presence of a hypoxic zone within the tumor and 
poor patient outcome, and this could be explained by an increased number of cancer stem 
cells (Heddleston et al., 2010). This might also explain the disappointing results obtained in 
some studies of single-agent vascular-targeted treatments aimed at depriving the tumor of 
oxygen by inhibiting its ability to generate a neo-vasculature in the hope to kill cancer cells. 
A side effect of this strategy might be a significant increase in the pool of drug-resistant 
cancer stem cells. However this does not preclude combining anti-angiogenic strategies with 
other specific anti-cancer stem cell therapies. As stated above, hypoxia has been reported to 
significantly improve the cell reprogramming by which mature differentiated cells give rise 
to iPS (Yoshida et al., 2009). The capacity of cancer stem cells to modulate the tumor 
environment has also been suspected. In solid tumors, several arguments suggest that 
cancer stem cells, as they are capable to survive in low oxygen concentration, stimulate 
angiogenesis in response to HIF-dependent signaling. This will help to increase the oxygen 
level within the growing tumor which otherwise conduct to necrosis of the under 
oxygenated tumor mass. With growing knowledge, hypoxia has become a critical 
microenvironment parameter. Indeed, HIF expression in cancer stem cells is now described 
to be responsible for cell proliferation and tumor survival (Heddleston et al., 2010). Later on 
during disease progression, continuous or increasing hypoxic conditions can lead to specific 
activation of local enzymes such as reported for lysyl oxidase, a well-known enzyme that 
crosslinks collagen. This enzymatic activity does not seem important for cancer initiation but 
appear essential for metastasis through activation of the protein FAK phosphorylation that 
stimulates cell migration and contributes to cancer spread (Larsen et al., 2006). 
4.4 The perfect hide-out 
Alteration of the permanent crosstalk between cancer stem cells and their microenvironment 
deregulates the balance between dormant and activated stem cells, contributing to tumor 
resistance (Besancon et al., 2009; White et al., 2006). A consequent literature has documented 
this aspect of cancer biology in both the hematopoietic context and solid tumors (Hall et al., 
2007; Kleeff et al., 2007; Kaplan et al., 2006; Psaila et al., 2006; Tysnes and Bjerkvig, 2007; Lee 
and Herlyn, 2007b; Lee and Herlyn, 2007a; Mueller and Fusenig, 2004). The bone marrow 
microenvironment is largely involved in the pathogenesis and maintenance of malignant 
tumors of hematopoietic origin. In the microenvironment, leukemic stem cells represent a 
quiescent population of cells that are resistant to standard therapy and different from their 
normal counterparts. Moreover, mesenchymal stem cells, the second largest population of 
long-lived stem/progenitor cells in the bone marrow, could favor the growth of tumor cells 
and their survival by inducing anti-apoptotic signals and further resistance to 
chemotherapeutic agents, as reported in acute myeloid leukemia (Konopleva et al., 2009). 
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Integrins are known to be involved not only in regulating the proliferation of extracellular 
matrix (fibronectin) and stromal cells (osteoblasts, mesenchymal stem cells) but also in the 
chemoresistance of leukemic stem cells (Fernandez-Vidal et al., 2006; De Toni et al., 2006). 
Numerous studies indicate that cell-cell and cell-matrix adhesion molecules also protect 
tumors from treatments. Adhesive interactions between cells or between cells and the 
extracellular matrix can regulate apoptosis and cell survival in a wide variety of cell types. 
Several studies have demonstrated that drugs generate a stress-induced anti-apoptotic bcl-2 
signaling pathway implicating ┚1 integrin and fibronectin interaction (Damiano, 2002). 
Interestingly, anti-┚1 antibodies or antisense oligonucleotides enhance the apoptotic process 
(Hazlehurst et al., 2001). In small cell lung cancer, the emergence of resistance to 
chemotherapy has also been correlated to high expression of integrins in the extracellular 
matrix (Hodkinson et al., 2007). The authors have demonstrated that the extracellular 
matrix, via ┚1 integrin-mediated PI3-kinase activation, allows small cell lung cancer cells to 
escape treatment-induced cell cycle arrest, apoptosis and DNA damage. In the mammary 
system, it has also been demonstrated that β1-integrin plays a key role in treatment 
resistance (Park et al., 2008).  Interestingly, we have demonstrated that β1-integin interaction 
with its ligand is required to maintain mammary stem cells in their niche at immature stage. 
Indeed, by using β1 blocking antibodies we have been able to induce further stem cell 
differentiation (Bachelard-Cascales et al., 2010). Altogether, these observations suggest that 
resistant breast cancer stem cells use β1-integrin to hide in the niche. In solid tumors, the 
microenvironment can protect stem cells from the oxygen deprivation due to rapid tumor 
cell proliferation and abnormal vessel formation (Keith and Simon, 2007). Therefore, the 
niche provides cancer stem cells with physical and physiological protection from anti-cancer 
drugs (Elrick et al., 2005).  
5. A major target for cancer cure 
Accumulated data clearly indicate that stem cell niches are key and active elements in 
cancer biology: they are involved in tumor initiation, progression and maintenance and 
therefore constitute an important target in anti-cancer therapy (Adams and Scadden, 2006; 
White et al., 2006). Observations indicate that the stem cell niche remains one of the key 
targets for future developments in cancer treatment. Two main strategies are currently 
developed based on the reciprocal dependence of the cancer stem cells and their niches. One 
is to attempt to awake quiescent cancer stem cells from dormancy and the other is to make 
them leave their protective niche. One should however keep in mind that selective anti-
cancer stem cell treatments will not immediately eliminate differentiated cancer cells, and 
might therefore be prematurely dropped if their clinical activity is judged solely by the 
traditional response criteria of changes in the bulk of the tumor. This implies that re-
examining both pre-clinical and clinical drug development paradigms in order to include 
the cancer stem cell concept might revolutionize the treatment of many cancers. Some drugs 
are already available that could act, at least in part, by killing cancer stem cells; however, no 
complete cure has been obtained to date, suggesting that further experimentation with 
cancer stem cell-targeted therapy is required (Besancon et al., 2009). The major problem for 
people developing these new drugs is to selectively target cancer stem cells whereas 
preserving normal stem cells. This question is indeed critical, since many studies have 
highlighted the extensive phenotypic and functional similarities between normal and cancer 
stem cells. A possible solution could be based on the fact that interactions between cancer 
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stem cells and their environment are profoundly altered. The modified cell environment 
itself can even be considered a relevant treatment target, even if not malignant per se. Re-
establishing a normal niche might also normalize its dialogue with cancer stem cells and 
some can imagine that this will help, in cooperation with more conventional therapy, to 
knock over cancer stem cells.  
5.1 How to awake dormant stem cells 
In this regard, the crucial role of adhesive interactions between tumor cells and the stroma 
in response to chemotherapy has been deciphered in various systems (Damiano, 2002; 
Haslam and Woodward, 2003). In chronic myelogenous leukemia, with the market release 
of anti-tyrosine kinase inhibitors specific for the fusion onco-protein BCR-ABL (imatinib) 
(Druker et al., 2001) and because of its toxicity, interferon ┙ has been partially abandoned. 
But, interestingly, there is a re-emerging interest for interferon ┙ in this indication. CD34+ 
leukemic samples from patients with BCR-ABL expression have been reported to contain 
quiescent leukemic stem cells that are particularly resistant to tyrosine kinase inhibitor 
treatments (Graham et al., 2002). These cells also have a defective integrin-cytoskeletal 
association that conducts in vitro to their restricted mobility (Bhatia et al., 1999). We may 
hypothesize that this favors chronic myelogenous leukemia stem cell quiescence, but in vitro 
treatment with interferon ┙ restores the integrin-cytoskeletal association (Bhatia et al., 1999). 
A more recent study has shown that interferon ┙ can also deplete the pool of chronic 
myelogenous leukemia stem cells and trigger their differentiation, whereas imatinib is only 
able to inhibit advanced differentiated chronic myelogenous leukemia progenitors 
(Angstreich et al., 2005). In T-cell leukemia, Kayo and coworkers have demonstrated the 
existence of side-population cells with stem-like properties, and shown that interferon ┙ is 
able to trigger their differentiation and enhance their sensitivity to chemotherapy (Kayo et 
al., 2007). Consistent with these results, an advanced clinical phase 3 trial is currently 
exploring the efficacy of imatinib and interferon ┙ combination therapy for the treatment of 
chronic myelogenous leukemia. In addition, several recent studies have reported that agents 
which can activate quiescent/dormant cells, such as cytokines (G-CSF (Holtz et al., 2007) 
and interferon ┙) or other compounds (arsenic trioxide-AS2O3), can be efficiently used to 
induce cancer stem cell cycling (for review see (Essers and Trumpp, 2010)).  These examples 
indicate that it is possible to kill cancer stem cells by combining treatment approaches. It is 
necessary, first, to awake quiescent stem cells and direct them toward differentiation, likely 
associated with their release from tumor niches, thus rendering them more accessible to 
chemotherapy, and, second, to expose these stem cells to more conventional 
chemotherapeutic drugs (Konopleva et al., 2009). Finally, in glioma, evidence suggests that 
anti-angiogenic therapy might enhance the efficiency of chemotherapy by disrupting the 
vascular niche of stem cells (Folkins et al., 2007). The investigators propose that the loss of 
communication between stem cells and their niche elicits a reduction or loss of certain stem 
cell properties associated with drug resistance, including dormancy, high proliferation rate 
and DNA repair. These observations provide a rational explanation for the poor efficiency of 
anti-angiogenic therapies when used alone and suggest that their use in combination with 
chemotherapy might open new perspectives in cancer stem cell targeting. Indeed, the 
hypoxic tumor microenvironment favors cancer stem cell dormancy and survival, as we 
discussed earlier. Interestingly, HIF1α, in addition to its role on stem cell dormancy, has also 
been found to regulate stromal cell-derived factor 1 (SDF1/CXCL12) gene expression in 
endothelial cells that mediate the adhesion, migration and homing of CXCR4-expressing 
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stem cells. This has been proposed to create a hypoxic microenvironment that facilitates the 
recruitment, retention and resting of cancer stem cells. This hypothesis is supported by 
recent data demonstrating the sensitivity of leukemic stem cells to anthracyclines, 
doxorubicin and daunorubicin, mediated in part by the inhibitory effect of the HIF1α 
pathway. Direct inhibitors of HIF1α are currently under clinical development and 
evaluation (for review see (Konopleva et al., 2009)). These data suggest that targeting the 
hypoxic pathway might then not only help to release cancer stem cells from their niche (as 
discussed below) but also contribute to shift them from quiescence/dormancy to active 
cycling, rendering them sensitive to conventional anti-mitotic chemotherapies. 
5.2 How to release cancer stem cells from their niche 
The niche favors the homing and retention of normal and cancer stem cells which remain in 
this safe environment, away from circulating cytotoxic drugs, during treatment. This 
protective role is mediated in part by the chemokine receptor 4 (CXCR4) and its ligand, the 
stromal cell-derived factor 1 (SDF1/CXCL12) (Larochelle et al., 2006; Papayannopoulou, 
2004). Interestingly these molecules have been recently reported to be involved in stem cell 
dormancy (Trumpp et al., 2010). An antagonist of the CXCR4 receptor, AMD3100, has been 
investigated in several phase I to III clinical trials exploring hematopoietic stem cell 
mobilization in leukemic patients with the objective of proposing self-transplantation after 
cytotoxic chemotherapy (Larochelle et al., 2006). Also, disruption of the SDF1/CXCL12 axis 
during tumor progression has been shown to induce the migration of cancer stem cells and 
to make them re-accessible and therefore sensitive to cytotoxic drugs in various leukemia 
and solid tumors (Gazitt, 2004; Rubin et al., 2003; Yang et al., 2007; Burger and Burkle, 2007). 
AMD3100 is currently under clinical investigation in combination with a cocktail of 
mitoxantrone, etoposide and cytarabine (Burger and Burkle, 2007). The CXCR4/CXCL12 
axis also constitutes a good anti-cancer stem cell target in at least two solid tumor models, 
breast and prostate cancers. Inhibition of the CXCR4/CXCL12 axis using another antagonist 
of the CXCR4 receptor, TN14003, has been explored in a mouse breast cancer metastasis 
model (Liang et al., 2004). Injection of human breast MDA-MB-231 cancer cells into the tail 
vein of mice induced several lung metastases. In mice treated with TN14003, metastases 
were dramatically reduced (Liang et al., 2004). Even if no clear causative link can be 
established with cancer stem cell depletion by the CXCR4 antagonist these data, combined 
with results obtained with AMD3100, tend to validate the CXCR4/CXCL12 axis, when 
expressed in the cancer stem cell subpopulation, as a good candidate for new treatment 
strategies. As this pathway is shared by both normal and cancer stem cells, concerns have 
been raised about the potential toxicity of targeting the CXCR4/CXCL12 axis. Normal stem 
cells would normally be protected from treatments by their microenvironment but, when 
mobilized, be suddenly exposed to cytotoxic drugs. One solution would be to combine the 
CXCR4 antagonists with monoclonal antibodies (see below) that would target specifically 
cancer (stem) cells while sparing their normal counterparts. Another possible approach for 
releasing cancer stem cells from their microenvironment would be to inhibit their physical 
attachment to the components of the niche. Obvious targets are the integrins which have 
been shown to be involved in cancer stem cell maintenance and resistance, as discussed 
earlier. Interestingly, only few treatments have demonstrated efficacy against this 
abnormality which is particularly important in the stem cell compartment, likely including 
leukemic stem cells. Indeed, in the hematopoietic system interferon ┙ seems to be the most 
efficient, or at least the most documented, drug for restoring full normal functions of ┚1 
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integrin in chronic myelogenous leukemia cells (Bhatia et al., 1995a; Bhatia et al., 1995b). In 
chronic myelogenous leukemia, the role of the specific BCR-ABL fusion protein inhibitor 
imanitib on integrin correction is still debated as some studies report a partly restored 
integrin function in immature cells (Bhatia et al., 1998) while other indicate the inefficiency 
of the drug on integrin defects (Ramaraj et al., 2004; Wertheim et al., 2002). Novel 
therapeutic strategies must therefore be developed to inhibit integrin-mediated cell survival 
signals and likely improve response rates. This could be achieved by targeting the 
downstream signaling of the integrin pathway. It has been proposed that the integrin-linked 
kinase which interacts with the cytoplasmic domains of β1 and β3 integrins might constitute 
a good target. This kinase mediates a diversity of functions relating to its role in coupling 
integrins and growth factor receptors to downstream signaling pathways. Through its 
downstream targets protein kinase B/Akt and glycogen synthase kinase-3b, the integrin-
linked kinase appears to be involved in several oncogenesis-related events, including 
suppression of apoptosis and promotion of cell survival, as well as cell migration and 
invasion. Furthermore, increased integrin-linked kinase expression and activity have been 
correlated with malignancy in several human tumor types, including breast, prostate, brain, 
and colon carcinomas (Yoganathan et al., 2002). For example, the role of β1-integrin in 
maintaining mammary stem cells (Bachelard-Cascales et al., 2010) and in the resistance of 
breast cancer cells (Park et al., 2008) make integrin-linked kinase an interesting target to 
prevent relapse and/or metastasis in breast or any other type of cancer.  
5.3 Emerging strategies 
Cell-based therapy has been evaluated for many years in different diseases including cancer. 
Infusion of ex vivo-expanded mesenchymal stem cells has been proposed to enhance 
hematopoietic  stem cell engraftment, especially in the adjuvant setting to treat graft-versus-
host disease in cancer therapy (Khakoo et al., 2006), on the basis of anti-tumor properties of 
mesenchymal stem cells (Elzaouk et al., 2006; Ramasamy et al., 2007). Interestingly and 
surprisingly, several studies have reported that normal neural stem cells are able to move 
toward and attach to cancer stem cells in the central nervous system, which makes them 
eligible tools for the specific delivery of cytotoxic drugs to cancer stem cells (Sakariassen et 
al., 2007). There is increasing evidence that cancer stem cells in different types of tumors and 
leukemia share a number of common features, in particular their need of a close interaction 
with their microenvironment. This suggests that diagnostic and therapeutic monoclonal 
antibodies and other molecules may be applicable across tumor types.  Until recently, most 
antibody-based strategies targeted antigens expressed by mature differentiated or activated 
cells. Adhesion molecules, such as CD44 and members of the Integrin family, mainly 
mediate cell-cell interactions between normal and cancer stem cells and various components 
of the niche (Chan and Watt, 2001; Ghaffari et al., 1999; Dontu et al., 2005;Ruoslahti, 1999). 
Also the adhesion molecule CD44 has been demonstrated to be required in acute myeloid 
leukemia for the homing of leukemic stem cells to their microenvironment where they are 
maintained in an immature state (Jin et al., 2006).  Therefore the use of CD44 as a specific 
anti-cancer stem cell target has been investigated. Experiments using H90, a specific anti-
CD44 antibody, have shown that disturbance of CD44-mediated cell-cell or cell-extracellular 
matrix adhesion alters the homing and maintenance of acute myeloid leukemia stem cells. 
This causes their differentiation towards monocytic or granulocytic lineages and depletion 
of acute myeloid leukemia stem cells in the bone marrow. Moreover, H90-treated mice have 
shown a reduced homing capacity in secondary recipient organs such as spleen or the bone 
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marrow of non-injected bones. Interestingly, H90 effects are specific for acute myeloid 
leukemia stem cells and no homing disturbance is observed when using normal cord blood 
stem cells. A study performed in serially transplanted mice has shown that H90-treated 
mice do not developed leukemia, contrary to non-treated mice (Jin et al., 2006). A study 
using the humanized anti-CD44 antibody ARH460-16-2, which binds to human acute 
myeloid leukemia CD34+CD38neg cancer stem cells, has evidenced a convincing anti-tumor 
activity in an AML xenograft model (Abstract Number 3976, AACR2008). Moreover, 
because CD44 is also present and found effective in other cancer stem cells, such as in breast 
(Sheridan et al., 2006), prostate (Patrawala et al., 2007), colorectal (Dalerba et al., 2007), 
pancreatic (Li et al., 2007) and small cell lung (Gutova et al., 2007) cancers, the authors have 
demonstrated that this antibody also exerts broad effects in solid tumors (Abstract Number 
3975, AACR2008). The ARH460-16-2 antibody has already completed Pre-Investigational 
New Drug evaluation by the FDA, which opens new promising perspectives for cancer 
treatment. The discovery of new markers of cancer stem cells from different tumor types has 
led to the development of many monoclonal antibodies in order not only to characterize and 
isolate the cancer stem cells but also to target them for treatment (for review see (Deonarain, 
2008)). As therapeutic antibodies are about to enter large clinical trials, the next decade of 
translational research and development in this area should see marked improvement in 
cancer diagnosis, prevention and treatment.   
6. Concluding remarks 
It has been known that microenvironments that can impose normal tissue architecture can 
both suppress the malignant phenotype and instruct otherwise malignant multipotent cells 
to give origin to differentiated cells and engage in normal organ development. Aging, 
associated with an increase in the number of cell divisions in which the centrosome is not 
tightly associated with adherent junctions between cells, is suspected to decrease stem cell 
numbers within the niche. This indicates that the effect of aging on stem cells partly results 
from impaired niche regulation at different levels. In addition, there is accumulating 
evidence that continuous input from the microenvironment might also determine the risk 
and course of tumor development. The more insight we get into the stem cell niche, the 
more new questions and issues emerge. Among these could be the clarification of whether 
niches are transiently or permanently occupied, of how they maintain their activity and 
specialization through time, of how the organism controls the number, size and composition 
of these niches, and so much more. To complement the advancing knowledge of niche 
composition and characteristics before and after cancer development, the current challenge 
is to develop experimental models encompassing the complexity of three-dimensional tissue 
organization, multiple cell niches and extra-cellular-matrix composition and allowing to 
grasp the full significance of the microenvironment in normal and in cancer cells. This 
crucial step will achieve a full understanding of features and functions of the stem cell 
niches, a real “black master” involved in all phases of cancer development. These findings 
should translate into a double-barreled therapy targeting both the cancer stem cells and 
their tumor niche. This would allow elaborating treatments to target cancer stem cells within 
their niches and ensure access to deeply quiescent cancer stem cells, if such exist, in order to 
make cancer a curable disease. Complementary approaches, such as the recruitment of 
useful bystanders like immune cells, should help to kill cancer stem cells or destroy their 
supporting environment. Undoubtedly, a better understanding of cancer development will 
evolve into novel strategies of risk assessment, diagnosis, prognosis and therapy.  
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